Literature DB >> 21686683

Complete deletion of the aprataxin gene: ataxia with oculomotor apraxia type 1 with severe phenotype and cognitive deficit.

Grace Yoon1, Robyn Westmacott, Lynn Macmillan, Nada Quercia, Pantelitsa Koutsou, Anthi Georghiou, Kyproula Christodoulou, Brenda Banwell.   

Abstract

Ataxia with oculomotor apraxia type 1 (AOA1) is a recently described autosomal-recessive neurodegenerative condition of childhood onset. It is caused by mutations in the APTX gene, which encodes the protein aprataxin. Clinical features include gait and limb ataxia, dysarthria, oculomotor apraxia, mild peripheral neuropathy and progression of neurological deficits.1 Some patients manifest parkinsonian symptoms or mental retardation, although the latter has been reported predominantly in Japanese patients.2 We report a patient with homozygous deletion of APTX, who presented with behavioural changes (social withdrawal), and subsequent rapid progression of neurological symptoms associated with severe cognitive decline. We suggest that complete deletion of APTX is associated with a more severe phenotype than that associated with point mutations.

Entities:  

Year:  2009        PMID: 21686683      PMCID: PMC3029461          DOI: 10.1136/bcr.08.2008.0688

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  5 in total

1.  DNA single-strand break repair is impaired in aprataxin-related ataxia.

Authors:  Makito Hirano; Aya Yamamoto; Toshio Mori; Li Lan; Taka-aki Iwamoto; Masashi Aoki; Keiji Shimada; Yoshiko Furiya; Shingo Kariya; Hirohide Asai; Akira Yasui; Tomohisa Nishiwaki; Kyoko Imoto; Nobuhiko Kobayashi; Takao Kiriyama; Tetsuya Nagata; Noboru Konishi; Yasuto Itoyama; Satoshi Ueno
Journal:  Ann Neurol       Date:  2007-02       Impact factor: 10.422

2.  Cerebellar ataxia with oculomotor apraxia type 1: clinical and genetic studies.

Authors:  Isabelle Le Ber; Maria-Ceù Moreira; Sophie Rivaud-Péchoux; Céline Chamayou; François Ochsner; Thierry Kuntzer; Marc Tardieu; Gérard Saïd; Marie-Odile Habert; Geneviève Demarquay; Christian Tannier; Jean-Marie Beis; Alexis Brice; Michel Koenig; Alexandra Dürr
Journal:  Brain       Date:  2003-09-23       Impact factor: 13.501

3.  Aprataxin gene mutations in Tunisian families.

Authors:  R Amouri; M-C Moreira; M Zouari; G El Euch; C Barhoumi; M Kefi; S Belal; M Koenig; F Hentati
Journal:  Neurology       Date:  2004-09-14       Impact factor: 9.910

4.  Early-onset ataxia with ocular motor apraxia and hypoalbuminemia: the aprataxin gene mutations.

Authors:  H Shimazaki; Y Takiyama; K Sakoe; K Ikeguchi; K Niijima; J Kaneko; M Namekawa; T Ogawa; H Date; S Tsuji; I Nakano; M Nishizawa
Journal:  Neurology       Date:  2002-08-27       Impact factor: 9.910

5.  The neurodegenerative disease protein aprataxin resolves abortive DNA ligation intermediates.

Authors:  Ivan Ahel; Ulrich Rass; Sherif F El-Khamisy; Sachin Katyal; Paula M Clements; Peter J McKinnon; Keith W Caldecott; Stephen C West
Journal:  Nature       Date:  2006-09-10       Impact factor: 49.962

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.